Skip to main content
Top
Published in: Journal of Translational Medicine 1/2011

Open Access 01-12-2011 | Research

Inhibition of mitotic kinase Aurora suppresses Akt-1 activation and induces apoptotic cell death in all-trans retinoid acid-resistant acute promyelocytic leukemia cells

Authors: Duo-Rong Xu, Shan Huang, Zi-Jie Long, Jia-Jie Chen, Zheng-Zhi Zou, Juan Li, Dong-Jun Lin, Quentin Liu

Published in: Journal of Translational Medicine | Issue 1/2011

Login to get access

Abstract

Background

Aurora kinase ensures accurate chromosome segregation during cell cycle, maintaining genetic integrity in cell division. VX-680, a small-molecule Aurora kinase inhibitor, interferes with mitotic entry and formation of bipolar spindles. Here, we evaluated VX-680 as a potential agent for treatment of all-trans retinoid acid (ATRA)-resistant acute promyelocytic leukemia (APL) in vitro.

Methods

CD11b expression was utilized to assess cell differentiation by flow cytometry. Immunofluorescence staining was conducted to analyze formation of cell monopolar spindle. Cell proliferation was evaluated by MTT assay. Sub-G1 population and Annexin V/PI staining were used to measure cell apoptosis. Hoechst 33342 staining was applied for identifying morphological changes in nucleus of apoptotic cell. Aurora-A (Aur-A) activation and the signaling pathways involved in apoptosis were detected by Western blot. JC-1 probe was employed to measure mitochondrial depolarization.

Results

VX-680 inhibited Aur-A by reducing autophosphorylation at the activation site, Thr288, accompanied by producing monopolar mitotic spindles in APL cell line NB4-R2 that was resistant to ATRA. In addition, we found that VX-680 inhibited cell proliferation as assessed by MTT assay. Flow cytometry showed that VX-680 led to apoptotic cell death in both dose- and time-dependent manners by either Sub-G1 or Annexin V/PI analysis. Hoechst 33342 staining represented typical apoptotic cells with nuclear fragmentation in VX-680 treated cells. Importantly, VX-680 inhibition of Aurora kinase suppressed Akt-1 activation and induced mitochondrial depolarization, which eventually resulted in apoptosis by activation of caspase pathway, as indicated by increasing proteolytic cleavage of procaspase-3 and poly ADP ribose polymerase (PARP) in NB4-R2 cells.

Conclusions

Our study suggested potential clinical use of mitotic Aurora kinase inhibitor in targeting ATRA-resistant leukemic cells.
Appendix
Available only for authorised users
Literature
1.
go back to reference Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Woods WG, Ogden A, Weinstein H, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH: All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood. 2002, 100: 4298-302. 10.1182/blood-2002-02-0632.CrossRefPubMed Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Woods WG, Ogden A, Weinstein H, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH: All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood. 2002, 100: 4298-302. 10.1182/blood-2002-02-0632.CrossRefPubMed
2.
go back to reference Wang ZY, Chen Z: Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008, 111: 2505-15. 10.1182/blood-2007-07-102798.CrossRefPubMed Wang ZY, Chen Z: Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008, 111: 2505-15. 10.1182/blood-2007-07-102798.CrossRefPubMed
3.
go back to reference Chambon P: Adecade of molecular biology of retinoic acid receptors. FASEB J. 1996, 10: 940-54.PubMed Chambon P: Adecade of molecular biology of retinoic acid receptors. FASEB J. 1996, 10: 940-54.PubMed
4.
go back to reference Lin RJ, Sternsdorf T, Tini M, Evans RM: Transcriptional regulation in acute promyelocytic leukemia. Oncogene. 2001, 20: 7204-15. 10.1038/sj.onc.1204853.CrossRefPubMed Lin RJ, Sternsdorf T, Tini M, Evans RM: Transcriptional regulation in acute promyelocytic leukemia. Oncogene. 2001, 20: 7204-15. 10.1038/sj.onc.1204853.CrossRefPubMed
5.
go back to reference Marumoto T, Zhang D, Saya H: Aurora-A: a guardian of poles. Nat Rev Cancer. 2005, 5: 42-50. 10.1038/nrc1526.CrossRefPubMed Marumoto T, Zhang D, Saya H: Aurora-A: a guardian of poles. Nat Rev Cancer. 2005, 5: 42-50. 10.1038/nrc1526.CrossRefPubMed
6.
go back to reference Meraldi P, Honda R, Nigg EA: Aurora kinases link chromosome segregation and cell division to cancer susceptibility. Curr Opin Genet Dev. 2004, 14: 29-36. 10.1016/j.gde.2003.11.006.CrossRefPubMed Meraldi P, Honda R, Nigg EA: Aurora kinases link chromosome segregation and cell division to cancer susceptibility. Curr Opin Genet Dev. 2004, 14: 29-36. 10.1016/j.gde.2003.11.006.CrossRefPubMed
8.
go back to reference Macarulla T, Ramos FJ, Tabernero J: Aurora kinase family: a new target for anticancer drug. Recent Pat Anticancer Drug Discov. 2008, 3: 114-22. 10.2174/157489208784638785.CrossRefPubMed Macarulla T, Ramos FJ, Tabernero J: Aurora kinase family: a new target for anticancer drug. Recent Pat Anticancer Drug Discov. 2008, 3: 114-22. 10.2174/157489208784638785.CrossRefPubMed
9.
go back to reference Lee EC, Frolov A, Li R, Ayala G, Greenberg NM: Targeting Aurora kinases for the treatment of prostate cancer. Cancer Res. 2006, 66: 4996-5002. 10.1158/0008-5472.CAN-05-2796.CrossRefPubMed Lee EC, Frolov A, Li R, Ayala G, Greenberg NM: Targeting Aurora kinases for the treatment of prostate cancer. Cancer Res. 2006, 66: 4996-5002. 10.1158/0008-5472.CAN-05-2796.CrossRefPubMed
10.
go back to reference Li D, Zhu J, Firozi PF, Abbruzzese JL, Evans DB, Cleary K, Friess H, Sen S: Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res. 2003, 9: 991-7.PubMed Li D, Zhu J, Firozi PF, Abbruzzese JL, Evans DB, Cleary K, Friess H, Sen S: Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res. 2003, 9: 991-7.PubMed
11.
go back to reference Kaestner P, Stolz A, Bastians H: Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells. Mol Cancer Ther. 2009, 8: 2046-56. 10.1158/1535-7163.MCT-09-0323.CrossRefPubMed Kaestner P, Stolz A, Bastians H: Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells. Mol Cancer Ther. 2009, 8: 2046-56. 10.1158/1535-7163.MCT-09-0323.CrossRefPubMed
12.
go back to reference Tanaka T, Kimura M, Matsunaga K, Fukada D, Mori H, Okano Y: Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. Cancer Res. 1999, 59: 2041-4.PubMed Tanaka T, Kimura M, Matsunaga K, Fukada D, Mori H, Okano Y: Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. Cancer Res. 1999, 59: 2041-4.PubMed
13.
go back to reference Ulisse S, Baldini E, Toller M, Delcros JG, Guého A, Curcio F, De Antoni E, Giacomelli L, Ambesi-Impiombato FS, Bocchini S, D'Armiento M, Arlot-Bonnemains Y: Transforming acidic coiled-coil 3 and Aurora-A interact in human thyrocytes and their expression is deregulated in thyroid cancer tissues. Ann Surg Oncol. 2007, 14: 719-29. 10.1245/s10434-006-9178-6.CrossRef Ulisse S, Baldini E, Toller M, Delcros JG, Guého A, Curcio F, De Antoni E, Giacomelli L, Ambesi-Impiombato FS, Bocchini S, D'Armiento M, Arlot-Bonnemains Y: Transforming acidic coiled-coil 3 and Aurora-A interact in human thyrocytes and their expression is deregulated in thyroid cancer tissues. Ann Surg Oncol. 2007, 14: 719-29. 10.1245/s10434-006-9178-6.CrossRef
14.
go back to reference Mazumdar A, Henderson YC, El-Naggar AK, Sen S, Clayman GL: Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma. Head Neck. 2009, 31: 625-34. 10.1002/hed.21007.PubMedCentralCrossRefPubMed Mazumdar A, Henderson YC, El-Naggar AK, Sen S, Clayman GL: Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma. Head Neck. 2009, 31: 625-34. 10.1002/hed.21007.PubMedCentralCrossRefPubMed
15.
go back to reference Siu LL: Promising new targeted agents in head and neck cancer. Int J Radiat Oncol Biol Phys. 2007, 69: 59-60.CrossRef Siu LL: Promising new targeted agents in head and neck cancer. Int J Radiat Oncol Biol Phys. 2007, 69: 59-60.CrossRef
16.
go back to reference Huang XF, Luo SK, Xu J, Li J, Xu DR, Wang LH, Yan M, Wang XR, Wan XB, Zheng FM, Zeng YX, Liu Q: Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis inAurora-A-high acute myeloid leukemia. Blood. 2008, 111: 2854-65. 10.1182/blood-2007-07-099325.CrossRefPubMed Huang XF, Luo SK, Xu J, Li J, Xu DR, Wang LH, Yan M, Wang XR, Wan XB, Zheng FM, Zeng YX, Liu Q: Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis inAurora-A-high acute myeloid leukemia. Blood. 2008, 111: 2854-65. 10.1182/blood-2007-07-099325.CrossRefPubMed
17.
go back to reference Shi Y, Reiman T, Li W, Maxwell CA, Sen S, Pilarski L, Daniels TR, Penichet ML, Feldman R, Lichtenstein A: Targeting aurora kinases as therapy in multiple myeloma. Blood. 2007, 109: 3915-21. 10.1182/blood-2006-07-037671.PubMedCentralCrossRefPubMed Shi Y, Reiman T, Li W, Maxwell CA, Sen S, Pilarski L, Daniels TR, Penichet ML, Feldman R, Lichtenstein A: Targeting aurora kinases as therapy in multiple myeloma. Blood. 2007, 109: 3915-21. 10.1182/blood-2006-07-037671.PubMedCentralCrossRefPubMed
18.
go back to reference Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ: MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood. 2007, 109: 500-2. 10.1182/blood-2006-05-025049.CrossRefPubMed Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ: MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood. 2007, 109: 500-2. 10.1182/blood-2006-05-025049.CrossRefPubMed
19.
go back to reference Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL, Sawyers CL: Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest. 2007, 117: 2562-9. 10.1172/JCI30890.PubMedCentralCrossRefPubMed Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL, Sawyers CL: Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest. 2007, 117: 2562-9. 10.1172/JCI30890.PubMedCentralCrossRefPubMed
20.
go back to reference Crane R, Gadea B, Littlepage L, Wu H, Ruderman JV: Aurora A, meiosis and mitosis. Biol Cell. 2004, 96: 215-29. 10.1016/j.biolcel.2003.09.008.CrossRefPubMed Crane R, Gadea B, Littlepage L, Wu H, Ruderman JV: Aurora A, meiosis and mitosis. Biol Cell. 2004, 96: 215-29. 10.1016/j.biolcel.2003.09.008.CrossRefPubMed
21.
go back to reference Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN, Gandara DR: Aurora Kinases as Anticancer Drug Targets. Clin Cancer Res. 2008, 14: 1630-48. 10.1158/1078-0432.CCR-07-2179.CrossRef Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN, Gandara DR: Aurora Kinases as Anticancer Drug Targets. Clin Cancer Res. 2008, 14: 1630-48. 10.1158/1078-0432.CCR-07-2179.CrossRef
22.
go back to reference Wan XB, Long ZJ, Yan M, Xu J, Xia LP, Liu L, Zhao Y, Huang XF, Wang XR, Zhu XF, Hong MH, Liu Q: Inhibition of Aurora-A suppresses epithelial-mesenchymal transition and invasion by downregulating MAPK in nasopharyngeal carcinoma cells. Carcinogenesis. 2008, 29: 1930-7. 10.1093/carcin/bgn176.CrossRefPubMed Wan XB, Long ZJ, Yan M, Xu J, Xia LP, Liu L, Zhao Y, Huang XF, Wang XR, Zhu XF, Hong MH, Liu Q: Inhibition of Aurora-A suppresses epithelial-mesenchymal transition and invasion by downregulating MAPK in nasopharyngeal carcinoma cells. Carcinogenesis. 2008, 29: 1930-7. 10.1093/carcin/bgn176.CrossRefPubMed
23.
go back to reference Pan C, Yan M, Yao J, Xu J, Long Z, Huang H, Liu Q: Aurora kinase small molecule inhibitordestroys mitotic spindle, suppresses cell growth, and induces apoptosis in oral squamous cancer cells. Oral Oncology. 2008, 44: 639-45. 10.1016/j.oraloncology.2007.08.010.CrossRefPubMed Pan C, Yan M, Yao J, Xu J, Long Z, Huang H, Liu Q: Aurora kinase small molecule inhibitordestroys mitotic spindle, suppresses cell growth, and induces apoptosis in oral squamous cancer cells. Oral Oncology. 2008, 44: 639-45. 10.1016/j.oraloncology.2007.08.010.CrossRefPubMed
24.
go back to reference Guan Z, Wang XR, Zhu XF, Huang XF, Xu J, Wang LH, Wan XB, Long ZJ, Liu JN, Feng GK, Huang W, Zeng YX, Chen FJ, Liu Q: Aurora-A, a Negative Prognostic Marker, Increases Migration and Decreases Radiosensitivity in Cancer Cells. Cancer Res. 2007, 67: 10436-44. 10.1158/0008-5472.CAN-07-1379.CrossRefPubMed Guan Z, Wang XR, Zhu XF, Huang XF, Xu J, Wang LH, Wan XB, Long ZJ, Liu JN, Feng GK, Huang W, Zeng YX, Chen FJ, Liu Q: Aurora-A, a Negative Prognostic Marker, Increases Migration and Decreases Radiosensitivity in Cancer Cells. Cancer Res. 2007, 67: 10436-44. 10.1158/0008-5472.CAN-07-1379.CrossRefPubMed
25.
go back to reference Tallman MS, Nabhan C, Feusner JH, Rowe JM: Acute promyelocytic leukemia: evolving therapeutic strategies. Blood. 2002, 99: 759-67. 10.1182/blood.V99.3.759.CrossRefPubMed Tallman MS, Nabhan C, Feusner JH, Rowe JM: Acute promyelocytic leukemia: evolving therapeutic strategies. Blood. 2002, 99: 759-67. 10.1182/blood.V99.3.759.CrossRefPubMed
26.
go back to reference Avvisati G, Lo Coco F, Diverio D, Falda M, Ferrara F, Lazzarino M, Russo D, Petti MC, Mandelli F: AIDA (alltrans retinoic acid+idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood. 1996, 88: 1390-8.PubMed Avvisati G, Lo Coco F, Diverio D, Falda M, Ferrara F, Lazzarino M, Russo D, Petti MC, Mandelli F: AIDA (alltrans retinoic acid+idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood. 1996, 88: 1390-8.PubMed
27.
go back to reference Fenaux P, Wang ZZ, Degos L: Treatment of acute promyelocytic leukemia by retinoids. Curr Top Microbiol Immunol. 2007, 313: 101-28. 10.1007/978-3-540-34594-7_7.PubMed Fenaux P, Wang ZZ, Degos L: Treatment of acute promyelocytic leukemia by retinoids. Curr Top Microbiol Immunol. 2007, 313: 101-28. 10.1007/978-3-540-34594-7_7.PubMed
28.
go back to reference Takayama N, Kizaki M, Hida T, Kinjo K, Ikeda Y: Novel mutation in the PML/RARα chimeric gene exhibits dramatically decreased ligand-binding activity and confers acquired resistance to retinoic acid in acute promyelocytic leukemia. Experimental Hematology. 2001, 29: 864-72. 10.1016/S0301-472X(01)00651-8.CrossRefPubMed Takayama N, Kizaki M, Hida T, Kinjo K, Ikeda Y: Novel mutation in the PML/RARα chimeric gene exhibits dramatically decreased ligand-binding activity and confers acquired resistance to retinoic acid in acute promyelocytic leukemia. Experimental Hematology. 2001, 29: 864-72. 10.1016/S0301-472X(01)00651-8.CrossRefPubMed
29.
go back to reference Shao W, Benedetti L, Lamph WW, Nervi C, Miller WH: A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RAR alpha mutation. Blood. 1997, 89: 4282-9.PubMed Shao W, Benedetti L, Lamph WW, Nervi C, Miller WH: A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RAR alpha mutation. Blood. 1997, 89: 4282-9.PubMed
30.
go back to reference Witcher M, Shiu HY, Guo Q, Miller WH: Combination of retinoic acid and tumor necrosis factor overcomes the maturation block in a variety of retinoic acid-resistant acute promyelocytic leukemia cells. Blood. 2004, 104: 3335-42. 10.1182/blood-2004-01-0023.CrossRefPubMed Witcher M, Shiu HY, Guo Q, Miller WH: Combination of retinoic acid and tumor necrosis factor overcomes the maturation block in a variety of retinoic acid-resistant acute promyelocytic leukemia cells. Blood. 2004, 104: 3335-42. 10.1182/blood-2004-01-0023.CrossRefPubMed
31.
go back to reference Duprez E, Benoit G, Flexor M, Lillehaug JR, Lanotte M: A mutated PML/RARA found in the retinoid maturation resistant NB4 subclone, NB4-R2, blocks RARA and wild-type PML/RARA transcriptional activities. Leukemia. 2000, 14: 255-61. 10.1038/sj.leu.2401683.CrossRefPubMed Duprez E, Benoit G, Flexor M, Lillehaug JR, Lanotte M: A mutated PML/RARA found in the retinoid maturation resistant NB4 subclone, NB4-R2, blocks RARA and wild-type PML/RARA transcriptional activities. Leukemia. 2000, 14: 255-61. 10.1038/sj.leu.2401683.CrossRefPubMed
32.
go back to reference Licht JD, Chomienne C, Goy A, Chen A, Scott AA, Head DR: Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood. 1995, 85: 1083-94.PubMed Licht JD, Chomienne C, Goy A, Chen A, Scott AA, Head DR: Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood. 1995, 85: 1083-94.PubMed
33.
go back to reference Raghu KH, Yadav GK, Singh R, Prathapan A, Sharma S, Bhadauria S: Evaluation of adverse cardiac effects induced by arsenic trioxide, a potent anti-APL drug. J Environ Pathol Toxicol Oncol. 2009, 28: 241-52.CrossRefPubMed Raghu KH, Yadav GK, Singh R, Prathapan A, Sharma S, Bhadauria S: Evaluation of adverse cardiac effects induced by arsenic trioxide, a potent anti-APL drug. J Environ Pathol Toxicol Oncol. 2009, 28: 241-52.CrossRefPubMed
34.
go back to reference Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, Graham JA, Demur C, Hercend T, Diu-Hercend A, Su M, Golec JM, Miller KM: VX-680, a potent and selective small-molecule inhibitor of the aurora kinases, suppresses tumor growth in vivo. Nat Med. 2004, 10: 262-7. 10.1038/nm1003.CrossRefPubMed Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, Graham JA, Demur C, Hercend T, Diu-Hercend A, Su M, Golec JM, Miller KM: VX-680, a potent and selective small-molecule inhibitor of the aurora kinases, suppresses tumor growth in vivo. Nat Med. 2004, 10: 262-7. 10.1038/nm1003.CrossRefPubMed
35.
go back to reference Glover DM, Leibowitz MH, McLean DA, Parry H: Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell. 1995, 81: 95-105. 10.1016/0092-8674(95)90374-7.CrossRefPubMed Glover DM, Leibowitz MH, McLean DA, Parry H: Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell. 1995, 81: 95-105. 10.1016/0092-8674(95)90374-7.CrossRefPubMed
36.
go back to reference Briassouli P, Chan F, Savage K, Reis-Filho JS, Linardopoulos S: Aurora-A regulation of nuclear factor-kappaB signaling by phosphorylation of IkappaBalpha. Cancer Res. 2007, 67: 1689-95. 10.1158/0008-5472.CAN-06-2272.CrossRefPubMed Briassouli P, Chan F, Savage K, Reis-Filho JS, Linardopoulos S: Aurora-A regulation of nuclear factor-kappaB signaling by phosphorylation of IkappaBalpha. Cancer Res. 2007, 67: 1689-95. 10.1158/0008-5472.CAN-06-2272.CrossRefPubMed
37.
go back to reference Yao JE, Yan M, Guan Z, Pan CB, Xia LP, Li CX, Wang LH, Long ZJ, Zhao Y, Li MW, Zheng FM, Xu J, Lin DJ, Liu Q: Aurora-A down-regulates IkappaBalpha via Akt activation and interacts with insulin-like growth factor-1 induced phosphatidylinositol 3-kinase pathway for cancer cell survival. Mol Cancer. 2009, 8: 95-10.1186/1476-4598-8-95.PubMedCentralCrossRefPubMed Yao JE, Yan M, Guan Z, Pan CB, Xia LP, Li CX, Wang LH, Long ZJ, Zhao Y, Li MW, Zheng FM, Xu J, Lin DJ, Liu Q: Aurora-A down-regulates IkappaBalpha via Akt activation and interacts with insulin-like growth factor-1 induced phosphatidylinositol 3-kinase pathway for cancer cell survival. Mol Cancer. 2009, 8: 95-10.1186/1476-4598-8-95.PubMedCentralCrossRefPubMed
38.
go back to reference Brenner D, Mak TW: Mitochondrial cell death effectors. Curr Opin Cell Biol. 2009, 21: 871-7. 10.1016/j.ceb.2009.09.004.CrossRefPubMed Brenner D, Mak TW: Mitochondrial cell death effectors. Curr Opin Cell Biol. 2009, 21: 871-7. 10.1016/j.ceb.2009.09.004.CrossRefPubMed
40.
go back to reference Billottet C, Banerjee L, Vanhaesebroeck B, Khwaja A: Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation. Cancer Res. 2009, 69: 1027-36. 10.1158/0008-5472.CAN-08-2608.CrossRefPubMed Billottet C, Banerjee L, Vanhaesebroeck B, Khwaja A: Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation. Cancer Res. 2009, 69: 1027-36. 10.1158/0008-5472.CAN-08-2608.CrossRefPubMed
41.
go back to reference Kharas MG, Okabe R, Ganis JJ, Gozo M, Khandan T, Paktinat M, Gilliland DG, Gritsman K: Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice. Blood. 2010, 115: 1406-15. 10.1182/blood-2009-06-229443.PubMedCentralCrossRefPubMed Kharas MG, Okabe R, Ganis JJ, Gozo M, Khandan T, Paktinat M, Gilliland DG, Gritsman K: Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice. Blood. 2010, 115: 1406-15. 10.1182/blood-2009-06-229443.PubMedCentralCrossRefPubMed
Metadata
Title
Inhibition of mitotic kinase Aurora suppresses Akt-1 activation and induces apoptotic cell death in all-trans retinoid acid-resistant acute promyelocytic leukemia cells
Authors
Duo-Rong Xu
Shan Huang
Zi-Jie Long
Jia-Jie Chen
Zheng-Zhi Zou
Juan Li
Dong-Jun Lin
Quentin Liu
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2011
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-9-74

Other articles of this Issue 1/2011

Journal of Translational Medicine 1/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.